Obesity is a serious health problem that is additionally associated with a number of co-morbidities, including hypertension, coronary artery disease, and congestive heart failure. Overweight and obesity also increase the risk for cancer-related mortality and for all cause mortality and result in reduced life expectancy.
Lifestyle measures are the cornerstone of prevention and treatment of obesity. However, adding antiobesity agents can be considered in obese patients who did not achieve sufficient weight loss after lifestyle modifications and if patients accept risks and benefits of these agents
Reductil is an effective pharmacotherapy for weight loss in obese patients when used as an adjunct to programmes that include a reduced-calorie diet, regular exercise, and behaviour modification. Reductil induces satiety by inhibiting the reuptake of serotonin and noradrenaline. It also increases thermogenesis and basal energy expenditure.
Studies have shown that even a modest weight loss as a result of Reductil and diet can significantly reduce the following life-risk factors:
- Weight reduction is also likely to improve appearance, which has a positive affect on self-esteem and motivation.
- Reduction of blood glucose levels (decreasing the risk of diabetes).
- Lowering of diastolic and systolic blood pressure (decreasing the risk of heart disease and strokes).
- Reduction in blood cholesterol levels (decreasing the risk of heart disease and strokes).
- Reduction in the cases of sleep apnea (irregular breathing during sleep).
Reduce your cravings for chocolate, carbohydrates, foods high in fat content with Reductil diet pills. Clinical studies have shown that individuals that take Reductil while dieting lose two times the weight as those individuals that attempt to diet without Reductil.